Teclistamab: Mechanism of action, clinical, and translational science

Abstract Multiple myeloma (MM) remains incurable despite improvements in treatment options. B‐cell maturation antigen (BCMA) is predominantly expressed in B‐lineage cells and represents a promising new target for MM. Teclistamab (TECVAYLITM) is the first T‐cell redirecting bispecific antibody approv...

Full description

Bibliographic Details
Published in:Clinical and Translational Science
Main Authors: Yue Guo, Natalia A. Quijano Cardé, Lijuan Kang, Raluca Verona, Arnob Banerjee, Rachel Kobos, Katherine Chastain, Clarissa Uhlar, Kodandaram Pillarisetti, Margaret Doyle, Jennifer Smit, Nahor Haddish‐Berhane, Daniele Ouellet
Format: Article
Language:English
Published: Wiley 2024-01-01
Online Access:https://doi.org/10.1111/cts.13717

Internet

https://doi.org/10.1111/cts.13717

Similar Items